Immunobiome, a company specializing in microbiome therapeutic research and development, announced on the 19th that it participated in the international microbiome event ‘Microbiome Connect ASIA’ and delivered a lecture on IMB002.
‘Microbiome Connect’ is an international event where over 200 biotech companies, investors, and academic institutions in the microbiome field gather. It is a venue where companies with top-tier technology and academic researchers come together to discuss microbiome-based drug development and build networks.
The Asia regional event was held in Seoul over two days starting from the 17th. Industry stakeholders from around the world, including Korea, Japan, China, India, Australia, the United States, France, and Denmark, gathered in one place.
Shinhyuk Lim, CEO of Immunobiome and a professor in the Department of Biotechnology at POSTECH, gave a lecture on the second day. He presented the clinical development plan for IMB002, a new live biotherapeutic product (LBP) candidate with strong anti-inflammatory activity.
Immunobiome plans to complete the Phase 1 clinical trial of IMB002 within next year. Following this, the company will proceed with an IPO (Initial Public Offering) to be listed on the KOSDAQ market. The goal is to be listed on the KOSDAQ market next year.
Shinhyuk Lim, CEO of Immunobiome, stated, “IMB002, which induces the generation of immune-regulatory T cells, has strong anti-inflammatory functions in IBD (inflammatory bowel disease) and other immune diseases. We will rapidly advance the Phase 1 clinical trial while quickly initiating the IPO process for listing on the KOSDAQ market.”
Meanwhile, Immunobiome confirmed in preclinical studies of IMB002 the alleviation of symptoms of inflammatory bowel disease, reduction of intestinal tissue damage compared to control groups, decrease in inflammatory cytokines, and expression of genes related to the recovery of intestinal epithelial tissue. In the upcoming Phase 1 clinical trial, the company plans to verify changes in gut microbiota composition and safety after administering IMB002 to healthy adults.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
